CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Catabasis Pharmaceuticals Inc. today announced that data from a Phase 1 clinical trial of its lead development candidate, CAT-2003, will be presented at the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14) in Washington, D.C. Catabasis’ chief medical officer, Joanne Donovan, M.D., Ph.D., will discuss the clinical data during the poster session from 9:45 to 10:30 a.m. EDT on Monday, March 31.
Details of the presentation follow:
CAT-2003 is a new chemical entity in Phase 2 clinical development for the treatment of severe hypertriglyceridemias. CAT-2003 leverages Catabasis’ proprietary SMART Linker technology to chemically conjugate two known lipid modulators, enabling selective intracellular delivery and synergistic activity. In animal models of severe hypertriglyceridemia, dose-dependent reductions in both fasting and post-prandial plasma triglycerides were observed with CAT-2003. In animal models of dyslipidemia, CAT-2003 also reduced LDL cholesterol. CAT-2003 currently is being studied in patients with severe hypertriglyceridemia.
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are based on the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating multiple targets in a disease pathway. Using its proprietary SMART Linker technology, Catabasis conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled an experienced team that is passionately committed to improving the lives of patients. Catabasis was founded in 2008 and is headquartered in Cambridge, Mass.
Please visit www.catabasis.com for more information.